Home
Development Programs
For Investors
News
About Us
- Our Name & Brandmark
- Team
Contact

Case Studies

Search for:

Or browse by category

News

All EMD General

EMDGeneral

Program: EMD-003

Developing a new cannabinoid formulation for stress, anxiety and depression.

Feb 25, 2021

Program: EMD-003

Development Programs

Groundbreaking Cannabinoid-based Medicines
Leading MDMA-Analogue Program
Research & Data Programs

For Investors

Stock Information
ASX Announcements
Presentations & Videos
Reports
Corporate Governance

Recent Tweets

Congratulations to Dr Stewart Washer & Matt Callahan who, as part of their work with Orthocell, have signed an excl… https://t.co/VmoxinQKkd

RT LetsTalkSciComm: 🚨🚨 Out now 🚨🚨 scidocmartin and _michaelwheeler chat with mwinlo, Managing Director of emyriaglobal about all thin…

©2022 Emyria Limited | Terms | Privacy | Website by Glide

Phone 08 6559 2800

Email info@emyria.com

First Name*
Last Name*
Email*
Post code
What news are you interested in?*
- Clinical news
- Patient news
- Investor news
- Partners news
CAPTCHA
Email
This field is for validation purposes and should be left unchanged.

Δ

Search for:

Hit enter to search or ESC to close

Home
Development Programs
For Investors
News
About Us
- Our Name & Brandmark
- Team
Contact

Call 08 6559 2800 Contact